Internal Reference Number: FOI_6968
Date Request Received: 17/01/2023 00:00:00
Date Request Replied To: 07/02/2023 00:00:00
This response was sent via: By Email
Request Summary: Usage of biologic and biosimilar products within Rheumatology.
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara | |
| Answer To Question 1: We have treated 977 patients in the last 3 months with the stated list of drugs split as follows: Abatacept 42 Adalimumab Biosimilars 289 Humira 29 Apremilast 6 Baricitinib 70 Certolizumab 39 Enbrel 11 Etanercept Biosimilars 129 Filgotinib 30 Golimumab 23 Infliximab Biosimilars 21 Remicade 8 Ixekizumab 35 Mabthera 7 Rituximab Biosimilars 92 Sarilumab <5 Secukinumab 20 Tocilizumab 50 Tofacitinib 30 Upadacitinib 42 Ustekinumab <5 | |
| Question Number 2: Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs. • Adalimumab [Humira] • Adalimumab Biosimilars • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] | |
| Answer To Question 2: We have treated 150 AxSpa patients in the last 3 months with the stated list of drugs, split as follows: Humira 12 Adalimumab Biosimilars 57 Certolizumab 13 Enbrel <5 Etanercept Biosimilars 29 Golimumab 10 Infliximab Biosimilars 12 Remicade <5 Ixekizumab <5 Secukinumab 12 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
